"As for off-label use, I think Pfeifer summed it up pretty...

"As for off-label use, I think Pfeifer summed it up pretty clearly. If you think that clinicians are going to prioritise a therapy approved for a tiny portion of a subset of a disease, where the company who make said therapy are openly telling you it should be used as a last resort, then I have some magic beans I would like to sell you."

I don't remember Michelle providing a summing up that was either terribly clear or resonated with how it works in the USA. The reader makes their own choice, I suppose.

We will find out pretty quickly either way so it's not worth arguing the point.

I reckon Mesoblast would be mad not to start the adult GVHD and it forms part of my statement above asking the BoDs at CYP for an update (if I was a holder).

A FDA agreed trial for P3 60-70 candidates versus a P2 60 candidate (that is around 20 deep currently)...........? Particularly since the approval for kids.........?




You're suggesting they ignore this development? I'm suggesting a statement would be nice at least.